Benavente M, Hakeem Z, Davis A, Murray N, Azadi P, Mace E
Sci Rep. 2024; 14(1):7938.
PMID: 38575779
PMC: 10995120.
DOI: 10.1038/s41598-024-58541-6.
Rodriguez Benavente M, Hughes H, Kremer P, Subedi G, Barb A
Immunology. 2023; 170(2):202-213.
PMID: 37218360
PMC: 10524233.
DOI: 10.1111/imm.13662.
Zhang W, Yin Q, Huang H, Lu J, Qin H, Chen S
Front Oncol. 2021; 11:628456.
PMID: 33928024
PMC: 8076796.
DOI: 10.3389/fonc.2021.628456.
Pradier A, Papaserafeim M, Li N, Rietveld A, Kaestel C, Gruaz L
Front Immunol. 2019; 10:556.
PMID: 30972058
PMC: 6445861.
DOI: 10.3389/fimmu.2019.00556.
Tagod M, Mizuta S, Sakai Y, Iwasaki M, Shiraishi K, Senju H
J Immunol Methods. 2019; 466:32-40.
PMID: 30654042
PMC: 6817948.
DOI: 10.1016/j.jim.2019.01.003.
Live Cell Labeling with Terpyridine Derivative Proligands to Measure Cytotoxicity Mediated by Immune Cells.
Sakai Y, Mizuta S, Kumagai A, Tagod M, Senju H, Nakamura T
ChemMedChem. 2017; 12(23):2006-2013.
PMID: 29110403
PMC: 5975248.
DOI: 10.1002/cmdc.201700626.
Targeted suppression of autoreactive CD8 T-cell activation using blocking anti-CD8 antibodies.
Clement M, Pearson J, Gras S, van den Berg H, Lissina A, Llewellyn-Lacey S
Sci Rep. 2016; 6:35332.
PMID: 27748447
PMC: 5066216.
DOI: 10.1038/srep35332.
Cytomegalovirus-Infected Cells Resist T Cell Mediated Killing in an HLA-Recognition Independent Manner.
Proff J, Walterskirchen C, Brey C, Geyeregger R, Full F, Ensser A
Front Microbiol. 2016; 7:844.
PMID: 27375569
PMC: 4899442.
DOI: 10.3389/fmicb.2016.00844.
Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing's sarcoma patients.
Schlegel P, Feuchtinger T, Nitschke-Gerard C, Seidel U, Lang A, Kyzirakos C
Bone Marrow Transplant. 2015; 50 Suppl 2:S72-6.
PMID: 26039213
DOI: 10.1038/bmt.2015.100.
In vitro Natural Killer Cell Immunotherapy for Medulloblastoma.
Fernandez L, Portugal R, Valentin J, Martin R, Maxwell H, Gonzalez-Vicent M
Front Oncol. 2013; 3:94.
PMID: 23626949
PMC: 3630393.
DOI: 10.3389/fonc.2013.00094.
Human β-cell killing by autoreactive preproinsulin-specific CD8 T cells is predominantly granule-mediated with the potency dependent upon T-cell receptor avidity.
Knight R, Kronenberg D, Zhao M, Huang G, Eichmann M, Bulek A
Diabetes. 2012; 62(1):205-13.
PMID: 22936177
PMC: 3526019.
DOI: 10.2337/db12-0315.
A novel technique to explore the functions of bronchial mucosal T cells in chronic obstructive pulmonary disease: application to cytotoxicity and cytokine immunoreactivity.
Lethbridge M, Kemeny D, Ratoff J, OConnor B, Hawrylowicz C, Corrigan C
Clin Exp Immunol. 2010; 161(3):560-9.
PMID: 20529083
PMC: 2962975.
DOI: 10.1111/j.1365-2249.2010.04198.x.
Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia.
Sorkin L, Otto M, Baldwin 3rd W, Vail E, Gillies S, Handgretinger R
Pain. 2010; 149(1):135-142.
PMID: 20171010
PMC: 3755890.
DOI: 10.1016/j.pain.2010.01.024.
Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis.
Ashraf S, Umana P, Mossner E, Ntouroupi T, Brunker P, Schmidt C
Br J Cancer. 2009; 101(10):1758-68.
PMID: 19904275
PMC: 2778542.
DOI: 10.1038/sj.bjc.6605355.
Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies.
Triplett B, Horwitz E, Iyengar R, Turner V, Holladay M, Gan K
Leukemia. 2009; 23(7):1278-87.
PMID: 19212329
PMC: 2851623.
DOI: 10.1038/leu.2009.21.
CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope.
Skowera A, Ellis R, Varela-Calvino R, Arif S, Huang G, Van-Krinks C
J Clin Invest. 2008; 118(10):3390-402.
PMID: 18802479
PMC: 2542849.
DOI: 10.1172/JCI35449.
Low concentrations of the soy phytoestrogen genistein induce proteinase inhibitor 9 and block killing of breast cancer cells by immune cells.
Jiang X, Patterson N, Ling Y, Xie J, Helferich W, Shapiro D
Endocrinology. 2008; 149(11):5366-73.
PMID: 18669594
PMC: 2584580.
DOI: 10.1210/en.2008-0857.
Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen.
Conaghan P, Ashraf S, Tytherleigh M, Wilding J, Tchilian E, Bicknell D
Br J Cancer. 2008; 98(7):1217-25.
PMID: 18349843
PMC: 2359646.
DOI: 10.1038/sj.bjc.6604289.
Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack.
Zell S, Geis N, Rutz R, Schultz S, Giese T, Kirschfink M
Clin Exp Immunol. 2007; 150(3):576-84.
PMID: 17903221
PMC: 2219364.
DOI: 10.1111/j.1365-2249.2007.03507.x.
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.
Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, Merola G
Proc Natl Acad Sci U S A. 2007; 104(30):12468-73.
PMID: 17636117
PMC: 1920540.
DOI: 10.1073/pnas.0705226104.